
Patrizia Limonta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/970628/publications.pdf Version: 2024-02-01



Ρατριγία Γιμονιτά

#	Article	IF	CITATIONS
1	miR-205 Exerts Tumor-Suppressive Functions in Human Prostate through Down-regulation of Protein Kinase Cε. Cancer Research, 2009, 69, 2287-2295.	0.9	334
2	GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. Human Reproduction Update, 2016, 22, 358-381.	10.8	156
3	GnRH Receptors in Cancer: From Cell Biology to Novel Targeted Therapeutic Strategies. Endocrine Reviews, 2012, 33, 784-811.	20.1	137
4	The Luteinizing Hormone-Releasing Hormone Receptor in Human Prostate Cancer Cells: Messenger Ribonucleic Acid Expression, Molecular Size, and Signal Transduction Pathway1. Endocrinology, 1999, 140, 5250-5256.	2.8	123
5	The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Frontiers in Neuroendocrinology, 2003, 24, 279-295.	5.2	114
6	Role of Endoplasmic Reticulum Stress in the Anticancer Activity of Natural Compounds. International Journal of Molecular Sciences, 2019, 20, 961.	4.1	93
7	LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opinion on Investigational Drugs, 2001, 10, 709-720.	4.1	90
8	Binding Characteristics of Hypothalamic Mu Opioid Receptors throughout the Estrous Cycle in the Rat. Neuroendocrinology, 1993, 58, 366-372.	2.5	79
9	The emerging role of paraptosis in tumor cell biology: Perspectives for cancer prevention and therapy with natural compounds. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188338.	7.4	79
10	Cancer Stem Cells—Key Players in Tumor Relapse. Cancers, 2021, 13, 376.	3.7	74
11	Effects of steroids on the brain opioid system. Journal of Steroid Biochemistry and Molecular Biology, 1995, 53, 343-348.	2.5	71
12	Î′â€Tocotrienol induces apoptosis, involving endoplasmic reticulum stress and autophagy, and paraptosis in prostate cancer cells. Cell Proliferation, 2019, 52, e12576.	5.3	69
13	Hypothalamic Opiatergic Tone During Pregnancy, Parturition and Lactation in the Rat. Neuroendocrinology, 1991, 53, 460-466.	2.5	65
14	Stimulatory and Inhibitory Effects of the Opioids on Gonadotropin Secretion. Neuroendocrinology, 1986, 42, 504-512.	2.5	60
15	Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets. Cells, 2020, 9, 460.	4.1	60
16	Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies. Cancer Treatment Reviews, 2013, 39, 647-663.	7.7	56
17	Vitamin E δ-tocotrienol triggers endoplasmic reticulum stress-mediated apoptosis in human melanoma cells. Scientific Reports, 2016, 6, 30502.	3.3	56
18	Gonadotropin-Releasing Hormone (GnRH) Receptors in Tumors: a New Rationale for the Therapeutical Application of GnRH Analogs in Cancer Patients?. Current Cancer Drug Targets, 2006, 6, 257-269.	1.6	54

PATRIZIA LIMONTA

#	Article	IF	CITATIONS
19	Locally Expressed LHRH Receptors Mediate the Oncostatic and Antimetastatic Activity of LHRH Agonists on Melanoma Cells. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3791-3797.	3.6	53
20	Clusterin Isoforms Differentially Affect Growth and Motility of Prostate Cells: Possible Implications in Prostate Tumorigenesis. Cancer Research, 2007, 67, 10325-10333.	0.9	53
21	Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol. Scientific Reports, 2018, 8, 587.	3.3	46
22	Epithelial-To-Mesenchymal Transition Markers and CD44 Isoforms Are Differently Expressed in 2D and 3D Cell Cultures of Prostate Cancer Cells. Cells, 2019, 8, 143.	4.1	46
23	Activation of the orphan nuclear receptor RORα counteracts the proliferative effect of fatty acids on prostate cancer cells: Crucial role of 5-lipoxygenase. International Journal of Cancer, 2004, 112, 87-93.	5.1	45
24	Anticancer properties of tocotrienols: A review of cellular mechanisms and molecular targets. Journal of Cellular Physiology, 2019, 234, 1147-1164.	4.1	45
25	Decrease of mu opioid receptors in the brain and in the hypothalamus of the aged male rat. Life Sciences, 1987, 40, 391-398.	4.3	44
26	Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. International Journal of Cancer, 1998, 76, 506-511.	5.1	42
27	In Vitro 3D Cultures to Model the Tumor Microenvironment. Cancers, 2021, 13, 2970.	3.7	40
28	GnRH in the Human Female Reproductive Axis. Vitamins and Hormones, 2018, 107, 27-66.	1.7	39
29	Cellular and molecular biology of cancer stem cells in melanoma: Possible therapeutic implications. Seminars in Cancer Biology, 2019, 59, 221-235.	9.6	39
30	Ca2+ overload- and ROS-associated mitochondrial dysfunction contributes to δ-tocotrienol-mediated paraptosis in melanoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2021, 26, 277-292.	4.9	39
31	Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines. PLoS ONE, 2015, 10, e0134396.	2.5	38
32	Type I Gonadotropin-Releasing Hormone Receptor Mediates the Antiproliferative Effects of GnRH-II on Prostate Cancer Cells. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1761-1767.	3.6	36
33	Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression Endocrine-Related Cancer, 2003, 10, 161-167.	3.1	35
34	Three-Dimensional Cell Cultures as an In Vitro Tool for Prostate Cancer Modeling and Drug Discovery. International Journal of Molecular Sciences, 2020, 21, 6806.	4.1	34
35	The Luteinizing Hormone-Releasing Hormone Receptor in Human Prostate Cancer Cells: Messenger Ribonucleic Acid Expression, Molecular Size, and Signal Transduction Pathway. Endocrinology, 1999, 140, 5250-5256.	2.8	30
36	Activation of the orphan nuclear receptor ROR? induces growth arrest in androgen-independent DU 145 prostate cancer cells. Prostate, 2001, 46, 327-335.	2.3	25

#	Article	IF	CITATIONS
37	Semi-preparative HPLC purification of δ-tocotrienol (δ-T3) from <i>Elaeis guineensis</i> Jacq. and <i>Bixa orellana</i> L. and evaluation of its <i>in vitro</i> anticancer activity in human A375 melanoma cells. Natural Product Research, 2018, 32, 1130-1135.	1.8	24
38	Beneficial effects of δ-tocotrienol against oxidative stress in osteoblastic cells: studies on the mechanisms of action. European Journal of Nutrition, 2020, 59, 1975-1987.	3.9	24
39	δâ€Tocotrienol sensitizes and reâ€sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPKâ€mediated apoptosis. Cell Proliferation, 2021, 54, e13111.	5.3	24
40	Role of the subfornical organ (SFO) in the control of gonadotropin secretion. Brain Research, 1981, 229, 75-84.	2.2	23
41	Unraveling the molecular mechanisms and the potential chemopreventive/therapeutic properties of natural compounds in melanoma. Seminars in Cancer Biology, 2019, 59, 266-282.	9.6	23
42	Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions. International Journal of Molecular Sciences, 2020, 21, 9511.	4.1	23
43	Distribution of kappa opioid receptors in the brain of young and old male rats. Life Sciences, 1989, 45, 2085-2092.	4.3	22
44	Modulation of the binding characteristics of hypothalamic mu opioid receptors in rats by gonadal steroids. Journal of Steroid Biochemistry and Molecular Biology, 1991, 40, 113-121.	2.5	22
45	Cholinergic inputs to the amygdala and the control of gonadotrophin release. European Journal of Endocrinology, 1980, 93, 1-6.	3.7	20
46	Testosterone and postnatal ontogenesis of hypothalamic μ ([3H]dihydromorphine) opioid receptors in the rat. Developmental Brain Research, 1991, 62, 131-136.	1.7	20
47	Growth of the androgen-dependent tumor of the prostate: Role of androgens and of locally expressed growth modulatory factors. Journal of Steroid Biochemistry and Molecular Biology, 1995, 53, 401-405.	2.5	20
48	Oncostatic activity of a thiazolidinedione derivative on human androgen-dependent prostate cancer cells. International Journal of Cancer, 2001, 92, 733-737.	5.1	20
49	The multifaceted roles of mitochondria at the crossroads of cell life and death in cancer. Free Radical Biology and Medicine, 2021, 176, 203-221.	2.9	20
50	Tocotrienols and Cancer: From the State of the Art to Promising Novel Patents. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 5-18.	1.6	19
51	Novel insights into GnRH receptor activity: Role in the control of human glioblastoma cell proliferation. Oncology Reports, 2009, 21, 1277-82.	2.6	18
52	Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy. Cancer Letters, 2022, 534, 215619.	7.2	18
53	Evaluation of a Stable Conadotropin-Releasing Hormone Analog in Mice for the Treatment of Endocrine Disorders and Prostate Cancer. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 613-623.	2.5	17
54	Mitochondrial functional and structural impairment is involved in the antitumor activity of Î'-tocotrienol in prostate cancer cells. Free Radical Biology and Medicine, 2020, 160, 376-390.	2.9	17

Patrizia Limonta

#	Article	IF	CITATIONS
55	Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor. International Journal of Oncology, 2015, 46, 243-253.	3.3	16
56	Androgen-dependent prostatic tumors: biosynthesis and possible actions of LHRH. Journal of Steroid Biochemistry and Molecular Biology, 1994, 49, 347-350.	2.5	15
57	Dual Targeting of Tumor and Endothelial Cells by Gonadotropin-Releasing Hormone Agonists to Reduce Melanoma Angiogenesis. Endocrinology, 2010, 151, 4643-4653.	2.8	15
58	Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression. Cancers, 2022, 14, 1614.	3.7	15
59	Melanoma Stem Cells Educate Neutrophils to Support Cancer Progression. Cancers, 2022, 14, 3391.	3.7	15
60	Unexpected effects of nalmefene, a new opiate antagonist, on the hypothalamic-pituitary-gonadal axis in the male rat. Steroids, 1985, 46, 955-965.	1.8	14
61	Gonadotropin-Releasing Hormone Agonists Sensitize, and Resensitize, Prostate Cancer Cells to Docetaxel in a p53-Dependent Manner. PLoS ONE, 2014, 9, e93713.	2.5	14
62	Locally Expressed LHRH Receptors Mediate the Oncostatic and Antimetastatic Activity of LHRH Agonists on Melanoma Cells. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3791-3797.	3.6	14
63	Species differences in the sensitivity to GnRH analogs. The Journal of Steroid Biochemistry, 1985, 23, 811-817.	1.1	13
64	Effects of aging on pituitary and testicular luteinizing hormone-releasing hormone receptors in the rat. Life Sciences, 1988, 42, 335-342.	4.3	13
65	Effect of ovarian steroids on the concentration of μ opiate receptors in different regions of the brain of the female rat. Pharmacological Research, 1989, 21, 91-92.	7.1	13
66	Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer. Cells, 2021, 10, 1133.	4.1	13
67	Further Evidence that Gonadal Steroids do not Modulate Brain Opiate Receptors in Male Rats Endocrinologia Japonica, 1987, 34, 521-529.	0.5	11
68	Targeting Hormonal Signaling Pathways in Castration Resistant Prostate Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2014, 9, 267-285.	1.6	10
69	Exploiting the Metabolic Consequences of PTEN Loss and Akt/Hexokinase 2 Hyperactivation in Prostate Cancer: A New Role for Ĩ-Tocotrienol. International Journal of Molecular Sciences, 2022, 23, 5269.	4.1	10
70	Characterization of a soluble LHRH-degrading activity in the rat ventral prostate. Prostate, 1993, 23, 315-328.	2.3	9
71	Molecular mechanisms of the antimetastatic activity of nuclear clusterin in prostate cancer cells. International Journal of Oncology, 2011, 39, 225-34.	3.3	8
72	Gonadotropin-releasing hormone agonists suppress melanoma cell motility and invasiveness through the inhibition of α3 integrin and MMP-2 expression and activity. International Journal of Oncology, 1992, 33, 405.	3.3	7

PATRIZIA LIMONTA

#	Article	IF	CITATIONS
73	Growth factors in steroid-responsive prostatic tumor cells. Steroids, 1996, 61, 222-225.	1.8	7
74	Effect of aging on opioid and LHRH receptors in the brain, pituitary, and testis of the male rat. Neurobiology of Aging, 1994, 15, 553-557.	3.1	6
75	Conadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. International Journal of Oncology, 2007, 30, 261.	3.3	6
76	Species differences in the sensitivity to a GnRH antagonist. Contraception, 1985, 32, 75-85.	1.5	5
77	Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. International Journal of Oncology, 2007, 30, 261-71.	3.3	4
78	New insights in melanoma biology: Running fast towards precision medicine. Seminars in Cancer Biology, 2019, 59, 161-164.	9.6	2
79	Castration Resistant Prostate Cancer: From Emerging Molecular Pathways to Targeted Therapeutic Approaches. Clinical Cancer Drugs, 2013, 1, 11-27.	0.3	1
80	LH-RH and Somatostatin: Examples of Peptidergic Control of Prostate Cancer Growth. Contributions To Oncology / Beitrage Zur Onkologie, 1995, 50, 332-344.	0.1	0
81	FROM EMERGING BIOLOGICAL INSIGHTS TO NOVEL TREATMENT STRATEGIES IN PROSTATE CANCER. Istituto Lombardo - Accademia Di Scienze E Lettere - Rendiconti Di Scienze, 2014, , .	0.0	0
82	Editorial (Thematic Issue: Novel Therapeutic Strategies for Castration-resistant Prostate Cancer:) Tj ETQq0 0 0 rg	BT/Qverlc	ock_10 Tf 50 3

83REPRODUCTIVE FUNCTION AND ANTITUMOR ACTIVITY: DIFFERENT ROLES FOR THE HYPOTHALAMIC
HORMONE GnRH. Istituto Lombardo - Accademia Di Scienze E Lettere - Incontri Di Studio, 0, , .0.00